Compare NINE & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NINE | CMMB |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 13.8M |
| IPO Year | 2018 | N/A |
| Metric | NINE | CMMB |
|---|---|---|
| Price | $0.35 | $2.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | ★ 857.6K | 91.3K |
| Earning Date | 10-30-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,171,000.00 | N/A |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | $1.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.59 | N/A |
| 52 Week Low | $0.34 | $2.24 |
| 52 Week High | $1.78 | $9.84 |
| Indicator | NINE | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 33.61 | 35.70 |
| Support Level | $0.43 | $2.44 |
| Resistance Level | $0.51 | $2.77 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.12 | 1.79 |
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.